301 BINNEY STREET, CAMBRIDGE, MA
Shareholder Vote Results from Scholar Rock Annual Meeting on June 4, 2026
Investor Presentation
Annual Report to Security Holders
Resubmits Biologics License Application (BLA) to FDA for Apitegromab for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)
Amended material disclosure
Earnings Release
Other Events
Q1
FY 2025
Q3
Q2
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Free Writing Prospectus
Correspondence
Submission Upload